Literature DB >> 4055058

Cefotaxime in the treatment of meningitis.

C E Cherubin, J LeFrock.   

Abstract

Information on 62 bacteriologically confirmed cases of bacterial meningitis treated with cefotaxime in this country was obtained retrospectively from infectious disease consultants. This series of cases differed markedly from the world cumulative case data so far presented. One of the two most common organisms treated was the pneumococcus (allergy to penicillin or misdiagnosis of the Gram stain were the major reasons given). Unanticipated bacteriologic successes were noted in two cases of staphylococcal meningitis secondary to parameningeal foci. The bacteriologic cure rate and survival rate were about 85%. Failure of monotherapy was seen in one case of pseudomonas meningitis, as well as in three of five cases of enterobacter meningitis. In addition, two cases of Escherichia coli meningitis which had inexplicably failed on moxalactam were cured with cefotaxime. Thus, overall not all gram-negative species and not all isolates of any particular species which cause meningitis can be successfully treated by cephalosporins. Data obtained during the investigative trials do not appear to be entirely predicative of what occurred during the free clinical use of an antibiotic. There is a need for the post-investigatory follow-up and surveillance of all newly introduced therapeutic agents.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4055058     DOI: 10.1007/BF01644222

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  18 in total

Review 1.  Gram-negative bacillary meningitis.

Authors:  R J Mangi; R Quintiliani; V T Andriole
Journal:  Am J Med       Date:  1975-12       Impact factor: 4.965

2.  Neonatal bacterial meningitis. Analysis of predisposing factors and outcome compared with matched control subjects.

Authors:  J C Overall
Journal:  J Pediatr       Date:  1970-04       Impact factor: 4.406

3.  Cefotaxime failure in group A streptococcal meningitis.

Authors:  P B Iannini; M J Kunkel
Journal:  JAMA       Date:  1982-10-15       Impact factor: 56.272

4.  Relapse of gram-negative bacillary meningitis after cefotaxime therapy.

Authors:  R W Bradsher
Journal:  JAMA       Date:  1982-09-10       Impact factor: 56.272

5.  A controlled study of intrathecal antibiotic therapy in gram-negative enteric meningitis of infancy. Report of the neonatal meningitis cooperative study group.

Authors:  G H McCracken; S G Mize
Journal:  J Pediatr       Date:  1976-07       Impact factor: 4.406

6.  Susceptibility of gram-positive cocci to various antibiotics, including cefotaxime, moxalactam, and N-formimidoyl thienamycin.

Authors:  C E Cherubin; M L Corrado; M F Sierra; M E Gombert; M Shulman
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

7.  Pharmacokinetics and clinical evaluation of cefotaxime in children suffering with purulent meningitis.

Authors:  P Bégué; D Floret; E Mallet; E J Raynaud; C Safran; J Sarlangues; G Teyssier
Journal:  J Antimicrob Chemother       Date:  1984-09       Impact factor: 5.790

8.  Open study of ceftazidime in serious infections due to multiply-resistant bacteria.

Authors:  J C Pechère; R Delisle
Journal:  J Antimicrob Chemother       Date:  1983-07       Impact factor: 5.790

9.  Listeria and gram-negative bacillary meningitis in New York City, 1972-1979. Frequent causes of meningitis in adults.

Authors:  C E Cherubin; J S Marr; M F Sierra; S Becker
Journal:  Am J Med       Date:  1981-08       Impact factor: 4.965

10.  Examination of gram-negative bacilli from meningitis patients who failed or relapsed on moxalactam therapy.

Authors:  R H Eng; C Cherubin; S M Smith; F Buccini
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

View more
  1 in total

1.  [Rational parameters in the treatment of bacterial meningitis with modern cephalosporins].

Authors:  O Brückner; M Trautmann
Journal:  Infection       Date:  1987       Impact factor: 3.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.